Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Infant Bacterial Therapeutics AB (publ) (9IB.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
4.3750+0.0400 (+0.92%)
At close: 02:07PM CET
Advertisement

Infant Bacterial Therapeutics AB (publ)

Bryggargatan 10
Stockholm 111 21
Sweden
46 7 62 19 37 38
https://www.ibtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. Staffan Stromberg Ph.D.Chief Exec. OfficerN/AN/A1967
Mr. Robert MolanderChief Commercial OfficerN/AN/A1965
Ms. Maria EkdahlChief Financial OfficerN/AN/A1973
Mr. Anders KronströmChief Operating OfficerN/AN/A1967
Prof. Jonas Rastad M.D., Ph.D.Chief Medical Officer & Chief Scientific OfficerN/AN/A1950
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Corporate Governance

Infant Bacterial Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement